secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2026-06-15T10:23:55+00:00
Accession:  0001437749-26-020562
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Filana shareholders approve 2018 Omnibus Incentive Plan amendment; authorized shares increased to 9M
--------------------------------------------------------------------------------

- Shareholders approved Amendment No. 2 to the 2018 Omnibus Incentive Plan, increasing authorized shares from 5M to 9M (4M added).
- Plan term extended through January 31, 2030; repricing of options/SARs explicitly prohibited without stockholder approval.
- Three directors elected: Richard J. Barry, Pierre Gravier, Claude Nicaise, M.D. (each ~8.9M for, ~1.5M withheld, ~14.1M broker non-votes).
- Ernst & Young ratified as auditor for FY2026 (22.7M for, 1.4M against). Non-binding say-on-pay passed (7.5M for, 2.8M against).
- 51% of outstanding shares (24.6M of 48.3M) represented at the meeting, constituting a quorum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000143774926020562/0001437749-26-020562-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000143774926020562/sava20260610_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-020562

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer